Phenserine - CAS 101246-66-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H23N3O2
Molecular Weight:
337.42
COA:
Inquire
Targets:
AChE
Description:
Phenserine, an analog of physostigmine, is an acetylcholinesterase (AChE) inhibitor (IC50= 24 nM) potentially for the treatment of Alzheimer Disease (AD).
Purity:
≥98% by HPLC
Synonyms:
(3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol 5-(N-phenylcarbamate); (-)-Eseroline phenylcarbamate; (-)-N-Phenylcarbamoyleseroline; (-)-Phenserine
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
PBHFNBQPZCRWQP-QUCCMNQESA-N
InChI:
InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1
Canonical SMILES:
CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
1.Why so few drugs for Alzheimer's disease? Are methods failing drugs?
Becker RE;Greig NH Curr Alzheimer Res. 2010 Nov;7(7):642-51.
Recent studies of Alzheimer's disease (AD) and other neuropsychiatric drug developments raise questions whether failures of some drugs occur due to flaws in methods. In three case studies of recent AD drug development failures with phenserine, metrifonate, and tarenflurbil we identified methodological lapses able to account for the failures. Errors in complex systems such as drug developments are both almost inescapable due to human mistakes and most frequently hidden at the time of occurrence and thereafter. We propose preemptive error management as a preventive strategy to exclude or control error intrusions into neuropsychiatric drug developments. We illustrate the functions we anticipate for a preemptive error management preventive strategy with a checklist and identify the limitations of this aspect of the proposal with three drug examples. This strategy applies core scientific practices to insure the quality of data within the current context of AD drug development practices.
2.FeCl
Kinthada LK;Medisetty SR;Parida A;Babu KN;Bisai A J Org Chem. 2017 Aug 18;82(16):8548-8567. doi: 10.1021/acs.joc.7b01232. Epub 2017 Aug 7.
An FeCl;3;-catalyzed efficient strategy for the allylation reactions of 3-hydroxy-2-oxindoles with allyltrimethylsilane has been developed. The reaction affords a variety of 2-oxindoles having quaternary center at the pseudobenzylic position in an operationally simple and inexpensive procedure. Control experiments using enantioenriched 3-hydroxy-2-oxindole show that the reaction proceeds through in situ generated 2H-indol-2-one (8). The methodology presents an efficient and concise access to the pyrroloindoline alkaloids (±)-deoxyeseroline (1a), (±)-esermethole (1b), (±)-physostigmine (1c), (±)-phenserine (1d), and (±)-physovenine (1e). Eventually, we extrapolated the scope of this methodology to the formal total syntheses of dimeric cyclotyrptamine alkaloids (±)-chimonanthine (3a), (±)-folicanthine (3c), and (±)-calycanthine (4).
3.Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.
al-Jafari AA;Kamal MA;Greig NH;Alhomida AS;Perry ER Biochem Biophys Res Commun. 1998 Jul 9;248(1):180-5.
The effect of phenserine, a novel cholinesterase inhibitor, was assessed for the first time on kinetic parameters of human erythrocyte acetylcholinesterase (AChE). Phenserine (0.025-0.40 microM) inhibited the activity of human erythrocyte AChE in a concentration-dependent fashion, the IC50 was 0.0453 microM. The Michaelis-Menten constant (K(m)) for the hydrolysis of acetylthiocholine iodide was found to be 0.124 mM and the Vmax was 0.980 mumol/min/mg protein. Dixon as well as Lineweaver-Burk plots and their secondary replots indicated that the nature of the inhibition was of the noncompetitive type. The value of Ki was estimated as 0.048 microM by the primary and secondary replots of the Dixon as well as secondary replots of the Lineweaver-Burk plot. A novel relationship between Ki and substrate concentration was also identified which permits more precise prediction of the specific type of noncompetitive inhibition of various enzymes by a wide variety of drugs, chemicals and, in some circumstances, by their own substrates.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AChE Products


AP2238
(CAS: 553681-56-4)

AP2238 is a inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

Ganstigmine hydrochloride
(CAS: 412044-92-9)

Ganstigmine hydrochloride is a selective inhibitor of AChE as a useful therapeutic drug for Alzheimer's disease patients with cognitive impairment accompanied b...

CAS 62732-44-9 Ipidacrine

Ipidacrine
(CAS: 62732-44-9)

Ipidacrine is a reversible acetylcholinesterase (AChE) inhibitor for the treatment of cognitive disorders.

CAS 314-03-4 Pimethixene

Pimethixene
(CAS: 314-03-4)

Pimethixene, also called as BP 400 or Calmixène, with antihistamine and anticholinergic properties it treats hyperactivity, anxiety, sleep disorders, and allerg...

CAS 120011-70-3 Donepezil HCl

Donepezil HCl
(CAS: 120011-70-3)

Donepezil is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively.

CAS 357-70-0 Galanthamine

Galanthamine
(CAS: 357-70-0)

Galanthamine, also called Razadyne, found in GALANTHUS and other AMARYLLIDACEAE, a cholinesterase inhibitor prescribed to treat symptoms of mild to moderate Alz...

CI 1002
(CAS: 149028-28-4)

CI 1002, an azepinoquinazoline derivative, has been found to be an acetylcholinesterase inhibitor that could probably be effective against cognitive dysfunction...

Neostigmine Iodide
(CAS: 1212-37-9)

This active molecular is a reversible acetylcholinesterase inhibitor as a parasympathomimetic compound under the development of Flamel Technologies. Neostigmine...

Chemical Structure

CAS 101246-66-6 Phenserine

Quick Inquiry

Verification code

Featured Items